
It created a buzz when the allergy group ALK announced in February that it would initiate a massive venture within food allergy, which is a massive market, far bigger than that ALK’s well-trodden territory of respiratory allergies.
On Thursday, the Denmark-based company reported that a phase I trial of a new tablet vaccine technology has been scheduled for the first half of 2022, initially testing it as a peanut allergy vaccine targeting the global market, which is valued around DKK 25bn (USD 2.85bn).
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app